- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine
Journal of Law, Medicine and Ethics 50 (2):380-384 (2022)
Abstract
Gene therapies to treat sickle cell disease are in development and are expected to have high costs. The large eligible population size — by far, the largest for a gene therapy — poses daunting budget challenges and threatens to exacerbate health disparities for Black patients, who make up the vast majority of American sickle cell patients.Other Versions
No versions found
My notes
Similar books and articles
Institutional Access to Gene Therapy for Sickle Cell Disease – Treatment on a Clinical Trial or Receive a Newly Approved Therapy?L. M. Johnson, B. S. Wilfond, A. D. Ray & L. Dawson - 2025 - American Journal of Bioethics 25 (4):145-146.
Gene Therapy for Sickle Cell Disease: Striking a Balance Between Approved Therapies and Clinical Trials.Yoram Unguru, Evelyn Okoro & Akpo Okoro - 2025 - American Journal of Bioethics 25 (4):151-153.
Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease.Consuela Albright, Kristin Walters, Shameka Poetry Thomas & Jada Wiggleton-Little - 2026 - Hastings Center Report 56 (3):9-14.
Clinical Trials or FDA-Approved Therapies? The Ethics of Sickle Cell Gene Therapy Access.Timothy P. Cripe & Anthony D. Villella - 2025 - American Journal of Bioethics 25 (4):147-149.
Allocation of Gene Therapy for Rare Diseases: FDA Approved Therapy or Clinical Trial for Patients with Sickle Cell Disease?Liza-Marie Johnson, Aimee C. Talleur & Akshay Sharma - 2025 - American Journal of Bioethics 25 (4):154-156.
Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.L. C. van Hooff, E. -M. Merz, A. S. Kidane Gebremeskel, J. A. de Jong, G. L. Burchell & J. E. Lunshof - 2025 - BMC Medical Ethics 26 (1):1-15.
Recruitment and Informed Consent for Experimental Gene Therapy Trials When New FDA-Approved Treatments are not Widely Available.Benjamin Slabaugh & Emily E. Anderson - 2025 - American Journal of Bioethics 25 (4):149-151.
Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine.Deanne Dunbar Dolan, Mildred K. Cho & Sandra Soo-Jin Lee - 2024 - AJOB Empirical Bioethics 15 (2):87-92.
Changing the Shape of Sickle Cell Disease Treatment: A Hermeneutic Study of a Case that Changed a Family and a Medical Practice.Nancy J. Moules, Catherine M. Laing & Gregory Guilcher - 2017 - Journal of Applied Hermeneutics 2017 (1).
Affordable pricing of CRISPR treatments is a pressing ethical imperative.Jon Rueda, Íñigo De Miguel Beriain & Lluis Montoliu - 2024 - CRISPR Journal.
Analytics
Added to PP
2022-07-29
Downloads
69 (#860,741)
6 months
19 (#600,705)
2022-07-29
Downloads
69 (#860,741)
6 months
19 (#600,705)
Historical graph of downloads
Citations of this work
A Just Genomics Needs an ELSI of Translation.Meghan C. Halley, Nate W. Olson, Euan A. Ashley, Aaron J. Goldenberg & Holly K. Tabor - 2024 - Hastings Center Report 54 (S2):126-135.
Try MATCHA Writer if you're interested in citing directly from PhilPapers and certifying your authorship.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation